Appointments at DSM, Codexis, USP and MonoSol Rx – People on the move
DSM Biomedical has named Christophe Dardel as its new president. Dardel, who replaces Steve Hartig, previously served as head of the firm’s Dyneema fibre business.
Stephen Tindal, a director at Catalent Pharma Solutions, has been appointed to the US Pharmacopeia (USP) advisory panel focused on liquid filled gelatin capsules. Tindal oversees softgel formulation and operations at Catalent.
TheraQuest Biosciences has bolstered its management team with the addition of two new executives. Danny Kao has been appointed senior vice president (SVP), of pharmaceutical development and Douglas Baum has been named as SVP of business development.
Peter Strumph has been appointed SVP of commercial operations at US biocatalyst firm Codexis. He joins the company from cardiovascular drug development group Nile Therapeutics where he served as CEO.
Drug delivery technology firm MonoSol Rx has appointed Eric Dadey as its new SVP of pharmaceutical development. Dadey, who will be involved in advancing the firm’s PharmaFilm delivery platform, previously served as VP of preclinical development at Transave Inhalation Biotherapeutics.
David Gelber has joined pharmaceutical firm Avrio Biopharmaceuticals as director of manufacturing. Before joining Avrio Gelber was director of operations at AAI Development Services.
Astellas Pharma has appointed Michael Tremblay as president of its Canadian subsidiary, replacing Fumiaki Sakurai. Tremblay has worked at Astellas for 10 years, most recently as VP of sales and marketing. Sakurai is returning to Japan to work in the Asia international unit.
Frank Morich is to leave his position of CEO of Noxxon Pharma to become EVP, international operations at Takeda Pharmaceutical. Ian Buchanan, a member of the Noxxon board of directors since 2007, will become interim CEO.
